Literature DB >> 30011093

Role of adenosine signaling in the pathogenesis of head and neck cancer.

Reza Khayami1, Younes Toroghian1, Amirhossein Bahreyni2, Afsane Bahrami3, Majid Khazaei4, Gordon A Ferns5, Safieh Ebrahimi6, Anvar Soleimani6, Hamid Fiuji7, Amir Avan3,8, Seyed Mahdi Hassanian6,8.   

Abstract

The concentrations of adenosine may increase under ischemic conditions in the tumor microenvironment, and then it enters the systemic circulation. Adenosine controls cancer progression and responses to therapy by regulating angiogenesis, cell survival, apoptosis, cell proliferation, and metastases in tumors. Hence, adenosine metabolism, adenosine-generating enzymes, and adenosine signaling are potentially novel therapeutic targets in a wide range of pathological conditions, including cerebral and cardiac ischemic diseases, inflammatory disorders, immunomodulatory disorders, and, of special interest in this review, cancer. This review summarizes the role of adenosine in the pathogenesis of head and neck cancer for a better understanding of how this may be applied to treating this type of cancer.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  adenosine; adenosine receptors; adenosine-generating enzymes; head and neck cancer

Mesh:

Substances:

Year:  2018        PMID: 30011093     DOI: 10.1002/jcb.27091

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  3 in total

Review 1.  Tumor-resident adenosine-producing mesenchymal stem cells as a potential target for cancer treatment.

Authors:  Samaneh Arab; Akram Alizadeh; Samira Asgharzade
Journal:  Clin Exp Med       Date:  2021-01-23       Impact factor: 3.984

2.  Primed mesenchymal stem cells package exosomes with metabolites associated with immunomodulation.

Authors:  Megan R Showalter; Benjamin Wancewicz; Oliver Fiehn; Joehleen A Archard; Shannon Clayton; Joseph Wagner; Peter Deng; Julian Halmai; Kyle D Fink; Gerhard Bauer; Brian Fury; Nicholas H Perotti; Michelle Apperson; Janelle Butters; Peter Belafsky; Gregory Farwell; Maggie Kuhn; Jan A Nolta; Johnathon D Anderson
Journal:  Biochem Biophys Res Commun       Date:  2019-03-26       Impact factor: 3.575

3.  CD73 downregulation by EGFR-targeted liposomal CD73 siRNA potentiates antitumor effect of liposomal doxorubicin in 4T1 tumor-bearing mice.

Authors:  Anvar Soleimani; Farshad Mirzavi; Sara Nikoofal-Sahlabadi; Amin Reza Nikpoor; Bita Taghizadeh; Mehdi Barati; Mohammad Soukhtanloo; Mahmoud Reza Jaafari
Journal:  Sci Rep       Date:  2022-06-21       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.